CD274 and non-small cell lung carcinoma: The OAK and POPLAR clinical trials showed that, among the previously treated NSCLC patients with high PD-L1 expression, the atezolizumab treatment could significantly improve the OS as compared to those treated with docetaxel [6, 7].